Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma
DYRK2, a dual-specificity tyrosine-(Y)-phosphorylation regulated kinase gene, is involved in regulating many processes such as cell proliferation, cell differentiation and cytokinesis. DYRK2 also plays an important role in many cancers, such as breast cancer, non-small cell lung cancer and esophagea...
Gespeichert in:
| Veröffentlicht in: | International journal of biological macromolecules 2015-11, Vol.81, p.809-817 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 817 |
|---|---|
| container_issue | |
| container_start_page | 809 |
| container_title | International journal of biological macromolecules |
| container_volume | 81 |
| creator | Wang, Yuchan Wu, Yaxun Miao, Xiaobing Zhu, Xinghua Miao, Xianjing He, Yunhua Zhong, Fei Ding, Linlin Liu, Jing Tang, Jie Huang, Yuejiao Xu, Xiaohong He, Song |
| description | DYRK2, a dual-specificity tyrosine-(Y)-phosphorylation regulated kinase gene, is involved in regulating many processes such as cell proliferation, cell differentiation and cytokinesis. DYRK2 also plays an important role in many cancers, such as breast cancer, non-small cell lung cancer and esophageal adenocarcinomas. In this study, we found that DYRK2 is associated with the proliferation of Non-Hodgkin's lymphoma (NHL) and cell adhesion mediated drug resistance (CAM-DR). Clinically, the mRNA and protein expression levels of DYRK2 are decreased in NHL tissues compared with reactive lymphoid hyperplasia tissues. Immunohistochemical analysis revealed that low expression of DYRK2 is associated with poor prognosis of NHL patients. Interestingly, knockdown of DYRK2 can promote cell proliferation via modulating cell cycle progression. Finally, we demonstrated that DYRK2 plays an important role in CAM-DR by regulating p27Kip1 expression. Importantly, DYRK2 knockdown reverses CAM-DR in NHL. Our research suggested that DYRK2 may be a novel therapeutic target for NHL. |
| doi_str_mv | 10.1016/j.ijbiomac.2015.08.067 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1751491694</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0141813015006145</els_id><sourcerecordid>1751491694</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-bb0b67ba2743b476b5afdc243f80c194d1598955338f14273c433f56381cbae83</originalsourceid><addsrcrecordid>eNqFkEFv1DAQhS1URLeFv1D5BpcET-w4zo1qW1jEAtICBw7Isp1J8ZLEWztbqf--Xm3LtaeRZt6befMRcgGsBAby_bb0W-vDaFxZMahLpkommxdkAappC8YYPyELBgIKBZydkrOUtrkra1CvyGkluQAFzYL8-eEHnJyfbmjo6dXvzZeK-slFNAkTdTgMdBfD4HuMZvZhonY_04h3GA_z5eXX4mqTDfRbmIpV6G7--eltouv7cfc3h3tNXvZmSPjmsZ6TXx-vfy5Xxfr7p8_Ly3XhuFRzYS2zsrGmagS3opG2Nn3nKsF7xRy0ooO6VW1dc656EFXDneC8ryVX4KxBxc_Ju-PenPV2j2nWo0-H8GbCsE8amhpEC7IVWSqPUhdDShF7vYt-NPFeA9MHtHqrn9DqA1rNlM5os_Hi8cbejtj9tz2xzIIPRwHmT-88Rp2cz2yx8xHdrLvgn7vxAHUWjEY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1751491694</pqid></control><display><type>article</type><title>Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wang, Yuchan ; Wu, Yaxun ; Miao, Xiaobing ; Zhu, Xinghua ; Miao, Xianjing ; He, Yunhua ; Zhong, Fei ; Ding, Linlin ; Liu, Jing ; Tang, Jie ; Huang, Yuejiao ; Xu, Xiaohong ; He, Song</creator><creatorcontrib>Wang, Yuchan ; Wu, Yaxun ; Miao, Xiaobing ; Zhu, Xinghua ; Miao, Xianjing ; He, Yunhua ; Zhong, Fei ; Ding, Linlin ; Liu, Jing ; Tang, Jie ; Huang, Yuejiao ; Xu, Xiaohong ; He, Song</creatorcontrib><description>DYRK2, a dual-specificity tyrosine-(Y)-phosphorylation regulated kinase gene, is involved in regulating many processes such as cell proliferation, cell differentiation and cytokinesis. DYRK2 also plays an important role in many cancers, such as breast cancer, non-small cell lung cancer and esophageal adenocarcinomas. In this study, we found that DYRK2 is associated with the proliferation of Non-Hodgkin's lymphoma (NHL) and cell adhesion mediated drug resistance (CAM-DR). Clinically, the mRNA and protein expression levels of DYRK2 are decreased in NHL tissues compared with reactive lymphoid hyperplasia tissues. Immunohistochemical analysis revealed that low expression of DYRK2 is associated with poor prognosis of NHL patients. Interestingly, knockdown of DYRK2 can promote cell proliferation via modulating cell cycle progression. Finally, we demonstrated that DYRK2 plays an important role in CAM-DR by regulating p27Kip1 expression. Importantly, DYRK2 knockdown reverses CAM-DR in NHL. Our research suggested that DYRK2 may be a novel therapeutic target for NHL.</description><identifier>ISSN: 0141-8130</identifier><identifier>EISSN: 1879-0003</identifier><identifier>DOI: 10.1016/j.ijbiomac.2015.08.067</identifier><identifier>PMID: 26341817</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Aged ; Cell Adhesion ; Cell adhesion mediated drug resistance (CAM-DR) ; Cell Cycle - genetics ; Cell Line, Tumor ; Cell Proliferation ; Cyclin-Dependent Kinase Inhibitor p27 ; Disease Progression ; Drug Resistance, Neoplasm - genetics ; Dyrk Kinases ; DYRK2 ; Female ; Gene Expression Regulation, Neoplastic ; Gene Knockdown Techniques ; Gene Silencing ; Humans ; Lymphoma, Large B-Cell, Diffuse - genetics ; Lymphoma, Large B-Cell, Diffuse - metabolism ; Lymphoma, Large B-Cell, Diffuse - pathology ; Lymphoma, Non-Hodgkin - diagnosis ; Lymphoma, Non-Hodgkin - genetics ; Lymphoma, Non-Hodgkin - metabolism ; Lymphoma, Non-Hodgkin - mortality ; Male ; Middle Aged ; Non-Hodgkin's lymphoma (NHL) ; p27Kip1 ; Phenotype ; Phosphorylation ; Prognosis ; Proliferation ; Protein Serine-Threonine Kinases - genetics ; Protein Serine-Threonine Kinases - metabolism ; Protein-Tyrosine Kinases - genetics ; Protein-Tyrosine Kinases - metabolism ; RNA, Small Interfering - genetics</subject><ispartof>International journal of biological macromolecules, 2015-11, Vol.81, p.809-817</ispartof><rights>2015 Elsevier B.V.</rights><rights>Copyright © 2015 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-bb0b67ba2743b476b5afdc243f80c194d1598955338f14273c433f56381cbae83</citedby><cites>FETCH-LOGICAL-c368t-bb0b67ba2743b476b5afdc243f80c194d1598955338f14273c433f56381cbae83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0141813015006145$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26341817$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Yuchan</creatorcontrib><creatorcontrib>Wu, Yaxun</creatorcontrib><creatorcontrib>Miao, Xiaobing</creatorcontrib><creatorcontrib>Zhu, Xinghua</creatorcontrib><creatorcontrib>Miao, Xianjing</creatorcontrib><creatorcontrib>He, Yunhua</creatorcontrib><creatorcontrib>Zhong, Fei</creatorcontrib><creatorcontrib>Ding, Linlin</creatorcontrib><creatorcontrib>Liu, Jing</creatorcontrib><creatorcontrib>Tang, Jie</creatorcontrib><creatorcontrib>Huang, Yuejiao</creatorcontrib><creatorcontrib>Xu, Xiaohong</creatorcontrib><creatorcontrib>He, Song</creatorcontrib><title>Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma</title><title>International journal of biological macromolecules</title><addtitle>Int J Biol Macromol</addtitle><description>DYRK2, a dual-specificity tyrosine-(Y)-phosphorylation regulated kinase gene, is involved in regulating many processes such as cell proliferation, cell differentiation and cytokinesis. DYRK2 also plays an important role in many cancers, such as breast cancer, non-small cell lung cancer and esophageal adenocarcinomas. In this study, we found that DYRK2 is associated with the proliferation of Non-Hodgkin's lymphoma (NHL) and cell adhesion mediated drug resistance (CAM-DR). Clinically, the mRNA and protein expression levels of DYRK2 are decreased in NHL tissues compared with reactive lymphoid hyperplasia tissues. Immunohistochemical analysis revealed that low expression of DYRK2 is associated with poor prognosis of NHL patients. Interestingly, knockdown of DYRK2 can promote cell proliferation via modulating cell cycle progression. Finally, we demonstrated that DYRK2 plays an important role in CAM-DR by regulating p27Kip1 expression. Importantly, DYRK2 knockdown reverses CAM-DR in NHL. Our research suggested that DYRK2 may be a novel therapeutic target for NHL.</description><subject>Adult</subject><subject>Aged</subject><subject>Cell Adhesion</subject><subject>Cell adhesion mediated drug resistance (CAM-DR)</subject><subject>Cell Cycle - genetics</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Cyclin-Dependent Kinase Inhibitor p27</subject><subject>Disease Progression</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Dyrk Kinases</subject><subject>DYRK2</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gene Knockdown Techniques</subject><subject>Gene Silencing</subject><subject>Humans</subject><subject>Lymphoma, Large B-Cell, Diffuse - genetics</subject><subject>Lymphoma, Large B-Cell, Diffuse - metabolism</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Lymphoma, Non-Hodgkin - diagnosis</subject><subject>Lymphoma, Non-Hodgkin - genetics</subject><subject>Lymphoma, Non-Hodgkin - metabolism</subject><subject>Lymphoma, Non-Hodgkin - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Non-Hodgkin's lymphoma (NHL)</subject><subject>p27Kip1</subject><subject>Phenotype</subject><subject>Phosphorylation</subject><subject>Prognosis</subject><subject>Proliferation</subject><subject>Protein Serine-Threonine Kinases - genetics</subject><subject>Protein Serine-Threonine Kinases - metabolism</subject><subject>Protein-Tyrosine Kinases - genetics</subject><subject>Protein-Tyrosine Kinases - metabolism</subject><subject>RNA, Small Interfering - genetics</subject><issn>0141-8130</issn><issn>1879-0003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEFv1DAQhS1URLeFv1D5BpcET-w4zo1qW1jEAtICBw7Isp1J8ZLEWztbqf--Xm3LtaeRZt6befMRcgGsBAby_bb0W-vDaFxZMahLpkommxdkAappC8YYPyELBgIKBZydkrOUtrkra1CvyGkluQAFzYL8-eEHnJyfbmjo6dXvzZeK-slFNAkTdTgMdBfD4HuMZvZhonY_04h3GA_z5eXX4mqTDfRbmIpV6G7--eltouv7cfc3h3tNXvZmSPjmsZ6TXx-vfy5Xxfr7p8_Ly3XhuFRzYS2zsrGmagS3opG2Nn3nKsF7xRy0ooO6VW1dc656EFXDneC8ryVX4KxBxc_Ju-PenPV2j2nWo0-H8GbCsE8amhpEC7IVWSqPUhdDShF7vYt-NPFeA9MHtHqrn9DqA1rNlM5os_Hi8cbejtj9tz2xzIIPRwHmT-88Rp2cz2yx8xHdrLvgn7vxAHUWjEY</recordid><startdate>20151101</startdate><enddate>20151101</enddate><creator>Wang, Yuchan</creator><creator>Wu, Yaxun</creator><creator>Miao, Xiaobing</creator><creator>Zhu, Xinghua</creator><creator>Miao, Xianjing</creator><creator>He, Yunhua</creator><creator>Zhong, Fei</creator><creator>Ding, Linlin</creator><creator>Liu, Jing</creator><creator>Tang, Jie</creator><creator>Huang, Yuejiao</creator><creator>Xu, Xiaohong</creator><creator>He, Song</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151101</creationdate><title>Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma</title><author>Wang, Yuchan ; Wu, Yaxun ; Miao, Xiaobing ; Zhu, Xinghua ; Miao, Xianjing ; He, Yunhua ; Zhong, Fei ; Ding, Linlin ; Liu, Jing ; Tang, Jie ; Huang, Yuejiao ; Xu, Xiaohong ; He, Song</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-bb0b67ba2743b476b5afdc243f80c194d1598955338f14273c433f56381cbae83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Cell Adhesion</topic><topic>Cell adhesion mediated drug resistance (CAM-DR)</topic><topic>Cell Cycle - genetics</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Cyclin-Dependent Kinase Inhibitor p27</topic><topic>Disease Progression</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Dyrk Kinases</topic><topic>DYRK2</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gene Knockdown Techniques</topic><topic>Gene Silencing</topic><topic>Humans</topic><topic>Lymphoma, Large B-Cell, Diffuse - genetics</topic><topic>Lymphoma, Large B-Cell, Diffuse - metabolism</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Lymphoma, Non-Hodgkin - diagnosis</topic><topic>Lymphoma, Non-Hodgkin - genetics</topic><topic>Lymphoma, Non-Hodgkin - metabolism</topic><topic>Lymphoma, Non-Hodgkin - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Non-Hodgkin's lymphoma (NHL)</topic><topic>p27Kip1</topic><topic>Phenotype</topic><topic>Phosphorylation</topic><topic>Prognosis</topic><topic>Proliferation</topic><topic>Protein Serine-Threonine Kinases - genetics</topic><topic>Protein Serine-Threonine Kinases - metabolism</topic><topic>Protein-Tyrosine Kinases - genetics</topic><topic>Protein-Tyrosine Kinases - metabolism</topic><topic>RNA, Small Interfering - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Yuchan</creatorcontrib><creatorcontrib>Wu, Yaxun</creatorcontrib><creatorcontrib>Miao, Xiaobing</creatorcontrib><creatorcontrib>Zhu, Xinghua</creatorcontrib><creatorcontrib>Miao, Xianjing</creatorcontrib><creatorcontrib>He, Yunhua</creatorcontrib><creatorcontrib>Zhong, Fei</creatorcontrib><creatorcontrib>Ding, Linlin</creatorcontrib><creatorcontrib>Liu, Jing</creatorcontrib><creatorcontrib>Tang, Jie</creatorcontrib><creatorcontrib>Huang, Yuejiao</creatorcontrib><creatorcontrib>Xu, Xiaohong</creatorcontrib><creatorcontrib>He, Song</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of biological macromolecules</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Yuchan</au><au>Wu, Yaxun</au><au>Miao, Xiaobing</au><au>Zhu, Xinghua</au><au>Miao, Xianjing</au><au>He, Yunhua</au><au>Zhong, Fei</au><au>Ding, Linlin</au><au>Liu, Jing</au><au>Tang, Jie</au><au>Huang, Yuejiao</au><au>Xu, Xiaohong</au><au>He, Song</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma</atitle><jtitle>International journal of biological macromolecules</jtitle><addtitle>Int J Biol Macromol</addtitle><date>2015-11-01</date><risdate>2015</risdate><volume>81</volume><spage>809</spage><epage>817</epage><pages>809-817</pages><issn>0141-8130</issn><eissn>1879-0003</eissn><abstract>DYRK2, a dual-specificity tyrosine-(Y)-phosphorylation regulated kinase gene, is involved in regulating many processes such as cell proliferation, cell differentiation and cytokinesis. DYRK2 also plays an important role in many cancers, such as breast cancer, non-small cell lung cancer and esophageal adenocarcinomas. In this study, we found that DYRK2 is associated with the proliferation of Non-Hodgkin's lymphoma (NHL) and cell adhesion mediated drug resistance (CAM-DR). Clinically, the mRNA and protein expression levels of DYRK2 are decreased in NHL tissues compared with reactive lymphoid hyperplasia tissues. Immunohistochemical analysis revealed that low expression of DYRK2 is associated with poor prognosis of NHL patients. Interestingly, knockdown of DYRK2 can promote cell proliferation via modulating cell cycle progression. Finally, we demonstrated that DYRK2 plays an important role in CAM-DR by regulating p27Kip1 expression. Importantly, DYRK2 knockdown reverses CAM-DR in NHL. Our research suggested that DYRK2 may be a novel therapeutic target for NHL.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26341817</pmid><doi>10.1016/j.ijbiomac.2015.08.067</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0141-8130 |
| ispartof | International journal of biological macromolecules, 2015-11, Vol.81, p.809-817 |
| issn | 0141-8130 1879-0003 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1751491694 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Cell Adhesion Cell adhesion mediated drug resistance (CAM-DR) Cell Cycle - genetics Cell Line, Tumor Cell Proliferation Cyclin-Dependent Kinase Inhibitor p27 Disease Progression Drug Resistance, Neoplasm - genetics Dyrk Kinases DYRK2 Female Gene Expression Regulation, Neoplastic Gene Knockdown Techniques Gene Silencing Humans Lymphoma, Large B-Cell, Diffuse - genetics Lymphoma, Large B-Cell, Diffuse - metabolism Lymphoma, Large B-Cell, Diffuse - pathology Lymphoma, Non-Hodgkin - diagnosis Lymphoma, Non-Hodgkin - genetics Lymphoma, Non-Hodgkin - metabolism Lymphoma, Non-Hodgkin - mortality Male Middle Aged Non-Hodgkin's lymphoma (NHL) p27Kip1 Phenotype Phosphorylation Prognosis Proliferation Protein Serine-Threonine Kinases - genetics Protein Serine-Threonine Kinases - metabolism Protein-Tyrosine Kinases - genetics Protein-Tyrosine Kinases - metabolism RNA, Small Interfering - genetics |
| title | Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T18%3A11%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Silencing%20of%20DYRK2%20increases%20cell%20proliferation%20but%20reverses%20CAM-DR%20in%20Non-Hodgkin's%20Lymphoma&rft.jtitle=International%20journal%20of%20biological%20macromolecules&rft.au=Wang,%20Yuchan&rft.date=2015-11-01&rft.volume=81&rft.spage=809&rft.epage=817&rft.pages=809-817&rft.issn=0141-8130&rft.eissn=1879-0003&rft_id=info:doi/10.1016/j.ijbiomac.2015.08.067&rft_dat=%3Cproquest_cross%3E1751491694%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1751491694&rft_id=info:pmid/26341817&rft_els_id=S0141813015006145&rfr_iscdi=true |